Cargando…
Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
Primary and acquired resistance of cancer to therapy is often associated with activation of nuclear factor kappa B (NF-κB). Parthenolide (PN) has been shown to inhibit NF-κB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in...
Autores principales: | Sztiller-Sikorska, Malgorzata, Czyz, Malgorzata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466132/ https://www.ncbi.nlm.nih.gov/pubmed/32823992 http://dx.doi.org/10.3390/ph13080194 |
Ejemplares similares
-
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres
por: Czyz, Malgorzata, et al.
Publicado: (2013) -
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations
por: Hartman, Mariusz L., et al.
Publicado: (2016) -
17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019) -
Natural Compounds' Activity against Cancer Stem-Like or Fast-Cycling Melanoma Cells
por: Sztiller-Sikorska, Malgorzata, et al.
Publicado: (2014) -
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
por: Hartman, Mariusz L., et al.
Publicado: (2020)